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ABSTRACT 
 
Assisted reproductive technologies (ARTs) are very efficient in producing embryos, 
however many of these embryos have poor viability. No more than 50% of IVF embryos 
complete preimplantation development (Hardy et al. 2001). The poor viability is 
manifested as a reduced rate of cell proliferation and increased rates of apoptosis in the 
early embryo, resulting in high rates of embryo mortality (Hardy et al. 2001). The 
reduced viability occurs as a response to a range of cellular stressors that are a 
consequence of embryo culture (Hardy et al. 2001). The stress of culture disrupts some 
survival signalling pathways, metabolism of substrates and induces redox stress (Hardy et 
al. 2001).  
 
The cellular stress sensor p53 is expressed in the early embryo but is normally kept at 
very low levels (Li et al. 2005). This latency may be breached in IVF embryos following 
culture of zygotes in vitro for 96 hours, resulting in the up-regulation and nuclear 
accumulation of p53 (Li et al. 2005). Activation of the p53 stress-sensing pathway in the 
early mouse embryo by culture in vitro causes a marked loss of their developmental 
competence (Li et al. 2005).  
 
This study aimed to establish whether benefits could be obtained by culturing mice IVF 
embryos in the presence of p53 protein inhibitors. IVF zygotes were cultured individua lly 
in 10µl drops of 1.25, 2.5, 5 or 10µM Pifithrin-a (PFTa) in 0.05% DMSO for 96 hours. 
On day 5 the development stage was assessed. Embryos reaching the blastocyst stage 
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were fixed and stained with Hoechst 33342 for total cell count and the proportion of 
nuclei with normal and abnormal morphology. There was an increase in the blastocyst 
rate, total cell count and the proportion of nuclei in a blastocyst with normal nuclei in 
10µM-treated embryos.  
 
This study also aimed to determine whether benefits could be obtained by incubating 
mouse IVF sperm with p53 protein inhibitors during IVF. IVF sperm was treated with 
1.25, 2.5, 5 or 10µM of PFTa  in 0.05% DMSO during incubation with oocytes for 6 
hours. Resulting zygotes were cultured for 96 hours individually in 10µl drops of MOD-
HTFM. On day 5 the development stage was assessed. Embryos reaching the blastocyst 
stage were fixed and stained with Hoechst 33342 for total cell count and the proportion of 
nuclei with normal and abnormal morphology. There was a reduction in the proportion of 
fragmented nuclei in blastocysts derived from 1.25 and 10µM-treated sperm. 10µM-
treated sperm increased the total cell count, the proportion of normal nuclei in a 
blastocyst and the blastocyst development rate. IVF sperm incubated with 1.25µM PFTa 
during insemination of oocytes increased the fertilisation rate.  
 
Another aim of this study was to establish whether p53 siRNA could inhibit p53 mRNA 
in mice IVF embryos and if so, whether this would improve embryo viability in culture. 
IVF zygotes were transfected with 15nM p53 small inhibiting RNA (siRNA) and 0.8% 
Oligofectamine Reagent immediately, 24 h, 48 h and 72 h after IVF then cultured 
individually in 10µl drops of MOD-HTFM for a total of 96 hours. On day 5 the 
blastocyst rate was assessed and immunofluorescence performed probing for p53. There 
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was no significant reduction in p53 expression and no improvement in blastocyst rate at 
any of the transfection times. However, there was a decrease in the proportion of nuclei 
which expressed p53 when p53 siRNA was transfected 72 hours after IVF. Also, it was 
determined that siRNA was efficiently being delivered into the preimplantation embryo 
with Oligofectamine Reagent. 
 
Lastly, this study aimed to determine whether mice sperm with p53 gene deletions have a 
selective advantage in fertilising the oocyte compared to their wild-type counterparts. 
p53+/- males were mated with p53+/+ females and the resulting zygotes genotyped after 
24 hours of culture. More than 50% of offspring had a p53+/+ ge notype. There was no 
selective advantage for p53 null sperm to fertilise the oocyte, there was actually a 
disadvantage. 
 
The selective disadvantage for p53 null sperm to fertilise the F1 hybrid oocyte in IVF 
compared to its wild-type counterparts may imply that p53 null sperm are not as viable 
and may have a survival disadvantage. The reduction in fertility of p53 null sperm in 
vitro infers that p53 function may be important for the fertility of the mouse sperm in 
vitro. 
 
The results of this thesis could establish means of improving human embryo viability in 
ART, some examples being P53 protein inhibition in preimplantation embryos during 
culture prior to transfer to the uterus, or P53 protein inhibition in IVF sperm. The use of 
the new technology, p53 siRNA was not effective  in inhibiting p53 expression, although 
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the build-up experiments determined that siRNA is efficiently delivered into the 
preimplantation embryo with Oligofectamine Reagent. The demonstration that p53 null 
sperm has a selective disadvantage in fertilising the oocyte compared to their wild-type 
counterparts does not indicate a positive selection pressure for naturally occurring 
mutations to this gene. And so, there is no concern regarding the genetic and epigenetic 
risks to progeny arising from assisted reproductive technologies with respect to sperm. 
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